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56 Poster Session Irecommendation. This includes patients who received only one of
a recommended tandem autologous HSCT, or who received an au-
tologous rather than a recommended allogeneic procedure. But
given the limitations of this analysis, we conclude that restrictions
imposed by health insurance coverage lead to significant delays in
implementing the treatment plan for patients who receive HSCT.147
MEASURING THE SYMPTOM BURDENOF CHRONIC GRAFT VERSUS HOST
DISEASE
Williams, L.A.1, Neumann, J.L.2, Couriel, D.R.3, Mendoza, T.R.1,
White, M.H.1, Zhang, Y.1, Cleeland, C.S.1 1The University of Texas
MD Anderson Cancer Center, Houston, TX; 2The University of Texas
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Center and Tennessee Oncology, Nashville, TN.
Significance: Chronic graft-versus-host disease (cGVHD) is an
autoimmune-like reaction that causes debilitating symptoms fol-
lowing allogeneic hematopoietic stem cell transplantation (al-
loHSCT). The major barrier to good management of these
symptoms is inadequate assessment. Theoretical Framework:
Symptom burden is the combined impact of all symptoms on a per-
son’s ability to function as one did prior to onset of disease and ther-
apy.Problem andPurpose:There is scant literature addressing the
symptom burden of cGVHD. Symptoms are subjective phenomena
and can only be accurately measured by patient report. The pur-
poses of this research are to develop a short, easily understood, valid,
and reliable patient questionnaire for measuring cGVHD symptom
burden and to describe the symptom burden of cGHVD. This ab-
stract reports preliminary results.Methods: The 13 core symptom
items and 6 interference items of the M. D. Anderson Symptom In-
ventory (MDASI), rated on a scale of 0 to 10, are the base for the
MDASI-GVH. In addition, 14 cGVHD-specific symptom items
were generated from interviews with patients and the ratings of an
expert panel. 128 patients with cGVHD and 64 patients post al-
loHSCTwithout cGVHDwill complete the MDASI-GVH. Infor-
mation on performance status, quality of life, and a repeat MDASI
will be collected on patients with cGVHD. Psychometric analyses
will reduce the number of items to the optimal set describing symp-
tom burden, determine predictive and discriminant validity, and es-
tablish internal consistency and test-retest reliability. The symptom
burden of cGVHD will be described through descriptive, correla-
tional, cluster, and factor analyses. Results: To date, 31 patients
with cGVHD and 7 without have completed the MDASI-GVH.
Average age is 49.3 years and 50% are male. Symptom severity
and interference is displayed in Table 1. Patients with cGVHD re-
ported a unique cluster of severe symptoms that included skin prob-
lems, eye problems, muscle weakness, and joint stiffness. By
February of 2008, we will report data on 45 patients with cGVHD
and 20 patients without cGVHD. Implications: Patients with
cGVHD tend to report more symptom severity and interference
than patients post alloHSCT without cGVHD. The most severe
symptoms patients with cGVHD report are cGVHD-specific. Fur-
ther testing is ongoing, but the MDASI-GVH is an easily com-
pleted method of quantifying symptoms of cGVHD for clinician
monitoring and use in trials testing methods to treat cGVHD.
Table 1. Symptom Severity and Interference in Patients With and
Without cGVHD
cGVHD No cGVHDItem Mean SD Mean SDSeverity of 13
Core Symptoms1.91 1.41 1.45 1.40Severity of 14 cGVHD-
Specific Symptoms2.24 1.41 1.53 0.87Severity of All Symptom 2.05 1.33 1.49 1.05
Symptom Interference 2.80 2.19 2.60 1.75SD 5 standard deviation.148
LONG-TERM NEUROCOGNITIVE FUNCTION OF PEDIATRIC PATIENTS
WITH SEVERE COMBINED IMMUNE DEFICIENCY (SCID): PRE AND
POST HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
Lin, M.1, Epport, K.2, Azen, C.2, Shah, A.J.3 1Keck School of Medicine,
Los Angeles, CA; 2Childrens Hospital Los Angeles, Los Angeles, CA;
3Childrens Hospital Los Angeles, Los Angeles, CA.
Background: Hematopoietic stem cell transplantation (HSCT)
is the only cure for patients with severe combined immunodefi-
ciency (SCID). The purpose of this study is to evaluate long-term
neurocognitive function of patients with SCID following myeloa-
blative chemotherapy and HSCT. Materials and Methods: Six-
teen pediatric patients diagnosed with SCID were tested using the
Bayley Scales of Infant Development and the validated Vineland
Adaptive Behavior Scales (VABS) pre- and 1-year post-HSCT.
Three years post HSCT there were 11 patients available for testing
and four patients were available 5 years post-HSCT. Patients
greater than 3 years of age were administered the Wechsler Pre-
school and Primary Scale of Intelligence (WPPSI). Both raw scores
and scaled scores were analyzed. Data were analyzed using multiple
regression analysis.Results:Therewas a significant decrease 1-year
post-HSCT in the Bayley Mental Developmental Index (MDI)
[92.5 (pre) vs. 70.8 (1 yr post); p5\0.0001] and the VABS [99.73
(pre) vs. 79.87 (1 year post), p5\0.0001]. There was no change
in the Bayley Psychomotor Development Scale (PDI) [82.4 (pre)
vs. 84.8 (1 year post), p 5 0.68]. There was a significant decrease
over time in the MDI [95.00 (pre) vs. 70.4 (1-year post) vs. 69.20
(3 yr post); p\ 0.0001), but no significant change between 1- and
3-years post- HSCT]. The PDI scores decreased over time [86.29
(pre) vs. 86 (1-year post) vs. 74.14 (3-years post), p 5 0.045]. Al-
though there was a decrease in scaled scores, there was not a loss
of skills. Analysis of raw scores showed that there was an increase
in the raw test scores, which indicated that these children acquired
developmental skills, but at a slower rate than normal infants and
toddlers. Conclusions: These findings may reflect the effects of
the isolation and prolonged hospitalization that characterizes the
immediate post transplant period. Patients miss out on social inter-
actions and learning opportunities that normally occur at their re-
spective stages of development. These restrictions keep patients
from acquiring developmentally appropriate cognitive skills as
well as gross and fine motor developmental milestones. Longitudi-
nal follow-up will be important to quantify acquisition of skills.LEUKEMIA149
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (Allo-HCT)
FOR PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC
LEUKEMIAS: IMPACT OF IMATINIB ON RISK OF RELAPSE AND SURVIVAL
Burke, M.J.1, Trotz, B.1, Luo, X.2, DeFor, T.E.2, Burns, L.J.3,
Baker, K.S.1,Weisdorf, D.J.3,Wagner, J.E.1, Verneris, M.R.1 1Univer-
sity of Minnesota, Minneapolis, MN; 2University of Minnesota, Minne-
apolis, MN; 3University of Minnesota, Minneapolis, MN.
The utility of Imatinib use in either the pre-or-post-transplant
period for Philadelphia positive (Ph1) Acute Lymphoblastic Leu-
kemia (ALL) is unknown. Additionally, there have been concerns
regarding Imatinib and cardiac toxicity (congestive heart failure)
in some series. Therefore, we investigated the outcome of trans-
plantation in patients with Ph1 ALL and treated with Imatinib.
Thirty-two patients with Ph1 ALL received allo-HCT at the Uni-
versity of Minnesota between 1999 and 2006. The median age at
HCT was 21.9 (range; 2.8–55.2) years. Eighteen (56.3%) patients
were male. Twenty patients were in first remission (CR1) prior to
HCT and 12-patients were in second remission (CR2). Donor
source was HLA matched and mismatched unrelated umbilical
cord blood (n 5 17), HLA matched sibling bone marrow (n 5 12)
and HLA matched unrelated bone marrow (n 5 3). All patients
were conditioned with cyclophosphamide and total body irradia-
tion. GVHD prophylaxis was with CSA/MTX (n 5 15), CSA/
MMF (n 5 13) or CSA methylprednisone/ATG (n 5 4). Of the
32 patients with Ph1 ALL, fifteen received Imatinib therapy pre/
